Nabriva Therapeutics PLC - ESG Rating & Company Profile powered by AI
This analysis of Nabriva Therapeutics PLC leverages intelligence from across the internet as well as from available disclosures by Nabriva Therapeutics PLC. The ESG rating includes 17 UN SDGs including: 'Quality Education', 'Responsible Production & Consumption' and 'Life below Water'. Check the bottom of the page for potential risks for Nabriva Therapeutics PLC based on sector, geography and size.
Nabriva Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 6.0, social score of 5.3 and governance score of 4.6.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 808 | Tilray Inc | 5.6 | High |
| 808 | Y-mAbs Therapeutics Inc | 5.6 | High |
| 835 | Nabriva Therapeutics PLC | 5.5 | High |
| 835 | Animalcare Group PLC | 5.5 | High |
| 835 | Bafna Pharmaceuticals Ltd | 5.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Nabriva Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Nabriva Therapeutics PLC report the average age of the workforce?
Sign up for free to unlockDoes Nabriva Therapeutics PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Nabriva Therapeutics PLC offer flexible work?
Sign up for free to unlockDoes Nabriva Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Nabriva Therapeutics PLC conduct supply chain audits?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Nabriva Therapeutics PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose water use targets?
Sign up for free to unlockDoes Nabriva Therapeutics PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Nabriva Therapeutics PLC have a product recall in the last two years?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Nabriva Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Nabriva Therapeutics PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose parental leave metrics?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Nabriva Therapeutics PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Nabriva Therapeutics PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Nabriva Therapeutics PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose its waste policy?
Sign up for free to unlockDoes Nabriva Therapeutics PLC report according to TCFD requirements?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose energy use targets?
Sign up for free to unlockDoes Nabriva Therapeutics PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Nabriva Therapeutics PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Nabriva Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.